426 related articles for article (PubMed ID: 26433008)
1. Economic evaluations of pharmacist-managed services in people with diabetes mellitus: a systematic review.
Wang Y; Yeo QQ; Ko Y
Diabet Med; 2016 Apr; 33(4):421-7. PubMed ID: 26433008
[TBL] [Abstract][Full Text] [Related]
2. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluations of clinical pharmacy services: 2006-2010.
Touchette DR; Doloresco F; Suda KJ; Perez A; Turner S; Jalundhwala Y; Tangonan MC; Hoffman JM
Pharmacotherapy; 2014 Aug; 34(8):771-93. PubMed ID: 24644086
[TBL] [Abstract][Full Text] [Related]
5. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
Yu J; Shah BM; Ip EJ; Chan J
J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
[TBL] [Abstract][Full Text] [Related]
6. Pharm-MD; an open-label, randomized controlled, phase II study to evaluate the efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients - study protocol for a randomized controlled trial.
Halalau A; Shelden D; Keeney S; Hehar J
Trials; 2018 Aug; 19(1):458. PubMed ID: 30143033
[TBL] [Abstract][Full Text] [Related]
7. Cost-benefit and cost-savings analyses of antiarrhythmic medication monitoring.
Snider M; Carnes C; Grover J; Davis R; Kalbfleisch S
Am J Health Syst Pharm; 2012 Sep; 69(18):1569-73. PubMed ID: 22935939
[TBL] [Abstract][Full Text] [Related]
8. The economic impact of pharmacist care for people living with HIV/AIDS: A systematic review.
Ahmed A; Dujaili JA; Hashmi FK; Awaisu A; Chaiyakunapruk N; Hasan SS
Explor Res Clin Soc Pharm; 2021 Sep; 3():100066. PubMed ID: 35480597
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of economic evaluations of pharmacist services.
Price E; Shirtcliffe A; Fisher T; Chadwick M; Marra CA
Int J Pharm Pract; 2023 Sep; 31(5):459-471. PubMed ID: 37543960
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of interventions in diabetes: a review of published economic evaluations in the UK setting, with an eye on the future.
Tucker DM; Palmer AJ
Prim Care Diabetes; 2011 Apr; 5(1):9-17. PubMed ID: 21071296
[TBL] [Abstract][Full Text] [Related]
11. Glycemic control and preventive care measures of indigent diabetes patients within a pharmacist-managed insulin titration program vs standard care.
Salvo MC; Brooks AM
Ann Pharmacother; 2012 Jan; 46(1):29-34. PubMed ID: 22202497
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluations of clinical pharmacy services in China: a systematic review.
Mi X; Su X; Jin Z; Zeng L; Li Z; Wang X; Zhang P; Zuo Y
BMJ Open; 2020 Jan; 10(1):e034862. PubMed ID: 31911528
[TBL] [Abstract][Full Text] [Related]
13. Development of a Pharmacoeconomic Model to Demonstrate the Effect of Clinical Pharmacist Involvement in Diabetes Management.
Ourth H; Nelson J; Spoutz P; Morreale AP
J Manag Care Spec Pharm; 2018 May; 24(5):449-457. PubMed ID: 29694293
[TBL] [Abstract][Full Text] [Related]
14. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidaemia: a systematic review.
Ahumada-Canale A; Quirland C; Martinez-Mardones FJ; Plaza-Plaza JC; Benrimoj S; Garcia-Cardenas V
Eur J Health Econ; 2019 Sep; 20(7):1103-1116. PubMed ID: 31218580
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost effectiveness of pharmacist input at the ward level: a systematic review and meta-analysis.
Dawoud DM; Smyth M; Ashe J; Strong T; Wonderling D; Hill J; Varia M; Dyer P; Bion J
Res Social Adm Pharm; 2019 Oct; 15(10):1212-1222. PubMed ID: 30389320
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature.
Gallagher J; McCarthy S; Byrne S
Int J Clin Pharm; 2014 Dec; 36(6):1101-14. PubMed ID: 25218003
[TBL] [Abstract][Full Text] [Related]
18. Identification of medication-related problems and health care provider acceptance of pharmacist recommendations in the DiabetesCARE program.
DeName B; Divine H; Nicholas A; Steinke DT; Johnson CL
J Am Pharm Assoc (2003); 2008; 48(6):731-6. PubMed ID: 19019801
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of chronic disease self-management for people with diabetes: a systematic review.
Teljeur C; Moran PS; Walshe S; Smith SM; Cianci F; Murphy L; Harrington P; Ryan M
Diabet Med; 2017 Aug; 34(8):1040-1049. PubMed ID: 27770591
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Geng J; Yu H; Mao Y; Zhang P; Chen Y
Pharmacoeconomics; 2015 Jun; 33(6):581-97. PubMed ID: 25736235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
